Presbyopia Solutions Comprehensive Study by Application (Eye Disease Treatment, Eye Disease Diagnosis, Eye Surgery), Treatment Type (Eyeglasses, Contact Lenses, Refractive Surgery, Lens Implants, Corneal Inlays), End User (Eye Care Clinics, Hospitals) Players and Region - Global Market Outlook to 2027

Presbyopia Solutions Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Presbyopia is problem related loss of eye sight. A person not able to see a nearby objects due to presbyopia. This problem is natural in aging population. Presbyopia usually becomes noticeable in early age of mid-40s and continues to worsen until around age 65. Presbyopia Solutions or treatment provides compensate for the inability of eyes to focus on nearby objects. The Solution option include wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia.

Highlights from Presbyopia Solutions Market Study
AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The key Players profiled in the report are Lenz Therapeutics (United States), Visus Therapeutics (United States), Novartis (Switzerland), Atia Vision (United States), Arctic Vision (China), Ocuphire Pharma (United States), LensGen (United States), Orasis (Israel), MAG Optics Inc. (United States) and Presbia PLC (Ireland). Additionally, other players that are part of this comprehensive study are Cellix Bio (India), Refocus Group, Inc. (United States), Tsubota Laboratory (Japan), Eyebright Medical Group (China), ClearSight LLC (United States) and Zinn Labs (United States).

Geographic Breakdown and Segment Analysis
The Global Presbyopia Solutions market presents a comprehensive analysis of the Presbyopia Solutions market by end-user/application (Eye Disease Treatment, Eye Disease Diagnosis and Eye Surgery), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Presbyopia Solutions industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Presbyopia Solutions market

Analyst at AMA have segmented the market study of Global Presbyopia Solutions market by Type, Application and Region.

Influencing Trend:
Innovation of Newest Generation Progressive Lenses, Innovation of New Presbyopia Solution Equipment and Rapid Uses of AI in Presbyopia Treatment and Solution

Market Growth Drivers:
Rising Cases of Gradual Loss of Eye Sight in Geriatric Populations and Rising Demand for Farsightedness, Nearsightedness and Astigmatism Checkup

Challenges:
Lack Of Expertise as Well as Extended Patients Care in Rural Areas, Proper Knowledge Related Presbyopia in Rural Areas and Lack of Proper Specialists Providing Presbyopia Solutions

Restraints:
Presbyopia Lens Implants Leads to Glare and Blurring of Eye and High Cost Surgery Option Associated with Presbyopia Solutions

Opportunities:
The Worldwide Advancement in Ophthalmology and Continuously Growing Healthcare Infrastructure

Market Developments Activities:
On 18 June 2020, Rexahn Pharmaceuticals Inc. agreed to merge with Ocuphire Pharma Inc., a privately held developer of therapies for eye disorders. Farmington Hills, Mich.-based Ocuphire Pharma is developing its lead drug candidate Nyxol eye drops for multiple front-of-the-eye indications, including night vision disturbances, reversal of pharmacologically-induced mydriasis or dilation of the pupil and presbyopia — the gradual loss of the eyes' ability to focus on nearby objects.
On 22 March 2022, Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, announced the launch of the first of two pivotal Phase 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia.



The market for Presbyopia Solutions is highly competitive with several global as well as local players in the market. The global players are trying various strategies such as service innovation and using various marketing strategies to gain a higher market share.

Key Target Audience
Presbyopia Solutions Providers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Application
  • Eye Disease Treatment
  • Eye Disease Diagnosis
  • Eye Surgery
By Treatment Type
  • Eyeglasses
  • Contact Lenses
  • Refractive Surgery
  • Lens Implants
  • Corneal Inlays

By End User
  • Eye Care Clinics
  • Hospitals

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Cases of Gradual Loss of Eye Sight in Geriatric Populations
      • 3.2.2. Rising Demand for Farsightedness, Nearsightedness and Astigmatism Checkup
    • 3.3. Market Challenges
      • 3.3.1. Lack Of Expertise as Well as Extended Patients Care in Rural Areas
      • 3.3.2. Proper Knowledge Related Presbyopia in Rural Areas
      • 3.3.3. Lack of Proper Specialists Providing Presbyopia Solutions
    • 3.4. Market Trends
      • 3.4.1. Innovation of Newest Generation Progressive Lenses
      • 3.4.2. Innovation of New Presbyopia Solution Equipment
      • 3.4.3. Rapid Uses of AI in Presbyopia Treatment and Solution
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Presbyopia Solutions, by Application, Treatment Type, End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Presbyopia Solutions (Value)
      • 5.2.1. Global Presbyopia Solutions by: Application (Value)
        • 5.2.1.1. Eye Disease Treatment
        • 5.2.1.2. Eye Disease Diagnosis
        • 5.2.1.3. Eye Surgery
      • 5.2.2. Global Presbyopia Solutions by: Treatment Type (Value)
        • 5.2.2.1. Eyeglasses
        • 5.2.2.2. Contact Lenses
        • 5.2.2.3. Refractive Surgery
        • 5.2.2.4. Lens Implants
        • 5.2.2.5. Corneal Inlays
      • 5.2.3. Global Presbyopia Solutions by: End User (Value)
        • 5.2.3.1. Eye Care Clinics
        • 5.2.3.2. Hospitals
      • 5.2.4. Global Presbyopia Solutions Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Presbyopia Solutions (Price)
  • 6. Presbyopia Solutions: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Lenz Therapeutics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Visus Therapeutics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Atia Vision (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Arctic Vision (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ocuphire Pharma (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. LensGen (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Orasis (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. MAG Optics Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Presbia PLC (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Presbyopia Solutions Sale, by Application, Treatment Type, End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Presbyopia Solutions (Value)
      • 7.2.1. Global Presbyopia Solutions by: Application (Value)
        • 7.2.1.1. Eye Disease Treatment
        • 7.2.1.2. Eye Disease Diagnosis
        • 7.2.1.3. Eye Surgery
      • 7.2.2. Global Presbyopia Solutions by: Treatment Type (Value)
        • 7.2.2.1. Eyeglasses
        • 7.2.2.2. Contact Lenses
        • 7.2.2.3. Refractive Surgery
        • 7.2.2.4. Lens Implants
        • 7.2.2.5. Corneal Inlays
      • 7.2.3. Global Presbyopia Solutions by: End User (Value)
        • 7.2.3.1. Eye Care Clinics
        • 7.2.3.2. Hospitals
      • 7.2.4. Global Presbyopia Solutions Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Presbyopia Solutions (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Presbyopia Solutions: by Application(USD Million)
  • Table 2. Presbyopia Solutions Eye Disease Treatment , by Region USD Million (2016-2021)
  • Table 3. Presbyopia Solutions Eye Disease Diagnosis , by Region USD Million (2016-2021)
  • Table 4. Presbyopia Solutions Eye Surgery , by Region USD Million (2016-2021)
  • Table 5. Presbyopia Solutions: by Treatment Type(USD Million)
  • Table 6. Presbyopia Solutions Eyeglasses , by Region USD Million (2016-2021)
  • Table 7. Presbyopia Solutions Contact Lenses , by Region USD Million (2016-2021)
  • Table 8. Presbyopia Solutions Refractive Surgery , by Region USD Million (2016-2021)
  • Table 9. Presbyopia Solutions Lens Implants , by Region USD Million (2016-2021)
  • Table 10. Presbyopia Solutions Corneal Inlays , by Region USD Million (2016-2021)
  • Table 11. Presbyopia Solutions: by End User(USD Million)
  • Table 12. Presbyopia Solutions Eye Care Clinics , by Region USD Million (2016-2021)
  • Table 13. Presbyopia Solutions Hospitals , by Region USD Million (2016-2021)
  • Table 14. South America Presbyopia Solutions, by Country USD Million (2016-2021)
  • Table 15. South America Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 16. South America Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 17. South America Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 18. Brazil Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 19. Brazil Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 20. Brazil Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 21. Argentina Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 22. Argentina Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 23. Argentina Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 24. Rest of South America Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 25. Rest of South America Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 26. Rest of South America Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 27. Asia Pacific Presbyopia Solutions, by Country USD Million (2016-2021)
  • Table 28. Asia Pacific Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 29. Asia Pacific Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 30. Asia Pacific Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 31. China Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 32. China Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 33. China Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 34. Japan Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 35. Japan Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 36. Japan Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 37. India Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 38. India Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 39. India Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 40. South Korea Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 41. South Korea Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 42. South Korea Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 43. Australia Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 44. Australia Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 45. Australia Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 46. Rest of Asia-Pacific Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 49. Europe Presbyopia Solutions, by Country USD Million (2016-2021)
  • Table 50. Europe Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 51. Europe Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 52. Europe Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 53. Germany Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 54. Germany Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 55. Germany Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 56. France Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 57. France Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 58. France Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 59. Italy Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 60. Italy Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 61. Italy Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 62. United Kingdom Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 63. United Kingdom Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 64. United Kingdom Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 65. Netherlands Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 66. Netherlands Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 67. Netherlands Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 68. Rest of Europe Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 69. Rest of Europe Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 70. Rest of Europe Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 71. MEA Presbyopia Solutions, by Country USD Million (2016-2021)
  • Table 72. MEA Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 73. MEA Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 74. MEA Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 75. Middle East Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 76. Middle East Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 77. Middle East Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 78. Africa Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 79. Africa Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 80. Africa Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 81. North America Presbyopia Solutions, by Country USD Million (2016-2021)
  • Table 82. North America Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 83. North America Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 84. North America Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 85. United States Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 86. United States Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 87. United States Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 88. Canada Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 89. Canada Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 90. Canada Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 91. Mexico Presbyopia Solutions, by Application USD Million (2016-2021)
  • Table 92. Mexico Presbyopia Solutions, by Treatment Type USD Million (2016-2021)
  • Table 93. Mexico Presbyopia Solutions, by End User USD Million (2016-2021)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Presbyopia Solutions: by Application(USD Million)
  • Table 105. Presbyopia Solutions Eye Disease Treatment , by Region USD Million (2022-2027)
  • Table 106. Presbyopia Solutions Eye Disease Diagnosis , by Region USD Million (2022-2027)
  • Table 107. Presbyopia Solutions Eye Surgery , by Region USD Million (2022-2027)
  • Table 108. Presbyopia Solutions: by Treatment Type(USD Million)
  • Table 109. Presbyopia Solutions Eyeglasses , by Region USD Million (2022-2027)
  • Table 110. Presbyopia Solutions Contact Lenses , by Region USD Million (2022-2027)
  • Table 111. Presbyopia Solutions Refractive Surgery , by Region USD Million (2022-2027)
  • Table 112. Presbyopia Solutions Lens Implants , by Region USD Million (2022-2027)
  • Table 113. Presbyopia Solutions Corneal Inlays , by Region USD Million (2022-2027)
  • Table 114. Presbyopia Solutions: by End User(USD Million)
  • Table 115. Presbyopia Solutions Eye Care Clinics , by Region USD Million (2022-2027)
  • Table 116. Presbyopia Solutions Hospitals , by Region USD Million (2022-2027)
  • Table 117. South America Presbyopia Solutions, by Country USD Million (2022-2027)
  • Table 118. South America Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 119. South America Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 120. South America Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 121. Brazil Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 122. Brazil Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 123. Brazil Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 124. Argentina Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 125. Argentina Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 126. Argentina Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 127. Rest of South America Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 128. Rest of South America Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 129. Rest of South America Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 130. Asia Pacific Presbyopia Solutions, by Country USD Million (2022-2027)
  • Table 131. Asia Pacific Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 132. Asia Pacific Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 133. Asia Pacific Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 134. China Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 135. China Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 136. China Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 137. Japan Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 138. Japan Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 139. Japan Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 140. India Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 141. India Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 142. India Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 143. South Korea Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 144. South Korea Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 145. South Korea Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 146. Australia Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 147. Australia Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 148. Australia Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 149. Rest of Asia-Pacific Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 150. Rest of Asia-Pacific Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 151. Rest of Asia-Pacific Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 152. Europe Presbyopia Solutions, by Country USD Million (2022-2027)
  • Table 153. Europe Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 154. Europe Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 155. Europe Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 156. Germany Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 157. Germany Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 158. Germany Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 159. France Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 160. France Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 161. France Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 162. Italy Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 163. Italy Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 164. Italy Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 165. United Kingdom Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 166. United Kingdom Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 167. United Kingdom Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 168. Netherlands Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 169. Netherlands Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 170. Netherlands Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 171. Rest of Europe Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 172. Rest of Europe Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 173. Rest of Europe Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 174. MEA Presbyopia Solutions, by Country USD Million (2022-2027)
  • Table 175. MEA Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 176. MEA Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 177. MEA Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 178. Middle East Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 179. Middle East Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 180. Middle East Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 181. Africa Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 182. Africa Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 183. Africa Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 184. North America Presbyopia Solutions, by Country USD Million (2022-2027)
  • Table 185. North America Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 186. North America Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 187. North America Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 188. United States Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 189. United States Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 190. United States Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 191. Canada Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 192. Canada Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 193. Canada Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 194. Mexico Presbyopia Solutions, by Application USD Million (2022-2027)
  • Table 195. Mexico Presbyopia Solutions, by Treatment Type USD Million (2022-2027)
  • Table 196. Mexico Presbyopia Solutions, by End User USD Million (2022-2027)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Presbyopia Solutions: by Application USD Million (2016-2021)
  • Figure 5. Global Presbyopia Solutions: by Treatment Type USD Million (2016-2021)
  • Figure 6. Global Presbyopia Solutions: by End User USD Million (2016-2021)
  • Figure 7. South America Presbyopia Solutions Share (%), by Country
  • Figure 8. Asia Pacific Presbyopia Solutions Share (%), by Country
  • Figure 9. Europe Presbyopia Solutions Share (%), by Country
  • Figure 10. MEA Presbyopia Solutions Share (%), by Country
  • Figure 11. North America Presbyopia Solutions Share (%), by Country
  • Figure 12. Global Presbyopia Solutions share by Players 2021 (%)
  • Figure 13. Global Presbyopia Solutions share by Players (Top 3) 2021(%)
  • Figure 14. Global Presbyopia Solutions share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Lenz Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 17. Lenz Therapeutics (United States) Revenue: by Geography 2021
  • Figure 18. Visus Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 19. Visus Therapeutics (United States) Revenue: by Geography 2021
  • Figure 20. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 22. Atia Vision (United States) Revenue, Net Income and Gross profit
  • Figure 23. Atia Vision (United States) Revenue: by Geography 2021
  • Figure 24. Arctic Vision (China) Revenue, Net Income and Gross profit
  • Figure 25. Arctic Vision (China) Revenue: by Geography 2021
  • Figure 26. Ocuphire Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 27. Ocuphire Pharma (United States) Revenue: by Geography 2021
  • Figure 28. LensGen (United States) Revenue, Net Income and Gross profit
  • Figure 29. LensGen (United States) Revenue: by Geography 2021
  • Figure 30. Orasis (Israel) Revenue, Net Income and Gross profit
  • Figure 31. Orasis (Israel) Revenue: by Geography 2021
  • Figure 32. MAG Optics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. MAG Optics Inc. (United States) Revenue: by Geography 2021
  • Figure 34. Presbia PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 35. Presbia PLC (Ireland) Revenue: by Geography 2021
  • Figure 36. Global Presbyopia Solutions: by Application USD Million (2022-2027)
  • Figure 37. Global Presbyopia Solutions: by Treatment Type USD Million (2022-2027)
  • Figure 38. Global Presbyopia Solutions: by End User USD Million (2022-2027)
  • Figure 39. South America Presbyopia Solutions Share (%), by Country
  • Figure 40. Asia Pacific Presbyopia Solutions Share (%), by Country
  • Figure 41. Europe Presbyopia Solutions Share (%), by Country
  • Figure 42. MEA Presbyopia Solutions Share (%), by Country
  • Figure 43. North America Presbyopia Solutions Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Lenz Therapeutics (United States)
  • Visus Therapeutics (United States)
  • Novartis (Switzerland)
  • Atia Vision (United States)
  • Arctic Vision (China)
  • Ocuphire Pharma (United States)
  • LensGen (United States)
  • Orasis (Israel)
  • MAG Optics Inc. (United States)
  • Presbia PLC (Ireland)
Additional players considered in the study are as follows:
Cellix Bio (India) , Refocus Group, Inc. (United States) , Tsubota Laboratory (Japan) , Eyebright Medical Group (China) , ClearSight LLC (United States) , Zinn Labs (United States)
Select User Access Type

Key Highlights of Report


Sep 2022 217 Pages 67 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2027
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • Lack Of Expertise as Well as Extended Patients Care in Rural Areas
  • Proper Knowledge Related Presbyopia in Rural Areas
  • Lack of Proper Specialists Providing Presbyopia Solutions

Know More About Global Presbyopia Solutions Market Report?